Global Deep Brain Stimulation Devices Pipeline Insight and Competitive Landscape 2020 Featuring 20 Companies & 23 Pipeline devices - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Deep Brain Stimulation Devices Pipeline Insight and Competitive Landscape, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

The Deep Brain Stimulation Devices - Pipeline Insight and Competitive Landscape, 2020, report provides comprehensive insights about 20+ companies and 23+ pipeline devices in the deep brain stimulation (DBS) devices pipeline landscape.

The DBS market is expected to undergo substantial growth in the coming years owning to an increasing prevalence of neurological disorders around the world. The growing aging population is also a major growth factor for the DBS devices market as it is more susceptible to neurological disorders like Parkinson's disease, Alzheimer's disease and Epilepsy. Therefore, due to an increase in demand of such devices, huge investment is being made on R&D activities in neurological sector, which is the major reason for an extensive pipeline in this segment.

This reports provides a detailed study of the emerging DBS devices along with competitive landscape to help better understand the emerging DBS devices.

Product Application

The DBS devices are used in Parkinson's disease, epilepsy, essential tremor, dystonia and obsessive compulsive disorder.

Major Players in DBS Devices

There are approx. 20+ key companies which are developing the products for DBS devices.

DirectSTIM DBS System: Aleva Neurotherapeutics SA.

Aleva's revolutionary DBS system incorporates directional electrode technology and is designed to be more precise and efficient, with optimized stimulation that will potentially reduce side effects. At present, Aleva is the only emerging technology company to be awarded the CE-Mark for Deep Brain Stimulation.

Picostim: Bioinduction Ltd

Picostim is in clinical trial phase. It is a miniaturized skull-mounted DBS device which is optimized to generate waveforms needed for stimulation of the subthalamic nucleus (STN) and STN region, employing a unique method of controlling stimulation current. The product undergoing clinical trial and is expected to be completed by 2023. It is a single center, open label, non-randomized design with the primary objective of showing similarity in control of motor symptoms for the Picostim device compared with previously published data for existing DBS devices.

Deep Brain Stimulation Devices Competitive Benchmarking

This segment of the reports provides analysis of the pipeline report to give a clear understanding of the comparative analysis.

The analysis is based on

• Brand Positioning of Leading companies
• Application
• Industry Collaborations

Deep Brain Stimulation Devices: Commercialization Activity

This segment of the report provides a detailed list of any commercial activity in the field of deep brain stimulator devices ranging from collaboration, mergers and acquisition, recent breakthrough among others.

Development Activities

• In August, 2020, the new Percept PC Neurostimulator with BrainSense developed by Medtronic was implanted to a patient in Penn State Health Milton S. Hershey Medical Center which become the first hospital in the state to implant a patient with a more personalized treatment for neurological disease
• Medtronic in August 2019 recalled the auto-registration feature of its StealthStation DBS software due to inaccuracies caused by minor patient movements during the auto-registration process when used with NexFrame stereotactic system during a DBS procedure. The problem resulted in 11 reports related to injuries and another 22 related to malfunctions, according to FDA.

Deep Brain Stimulation Devices: Reimbursement

The US

US reimbursement policy, Medicare covers DBS for the treatment of essential tremor and/or Parkinsonian tremor. Medicare only consider DBS devices to be reasonable and necessary if they are Food and Drug Administration (FDA) approved devices used in accordance with FDA approved protocols governing Category B Investigational Device Exemption (IDE) DBS clinical trials.

Key Players

• Adaptive Neuromodulation GmbH
• Adept Neuro SA
• Aleva Neurotherapeutics SA
• Bioinduction Limited
• Boston Scientific Corp
• Brainsway Ltd
• Cleveland Medical Devices Inc
• Cortera Neurotechnologies Inc
• Deep Brain Innovations, LLC
• Enspire DBS Therapy Inc
• Functional Neuromodulation Inc.
• Medtronic plc
• NeuroOne Inc
• Nexeon MedSystems Inc
• Wedge Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lvxfrp